NERV Minerva Neurosciences, Inc.
USHealthcareAs of 2026-07-09 16:00
Why NERV matters now
Minerva Neurosciences, Inc. (NERV) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.72 with +2.16% on the session and $33.0M in market capitalization; recent performance reads 1-month +2.52% and YTD +11.19%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-125.4M, and EPS of $-2.86. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17392.0%.
The latest indexable market news headline is "Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.00; recent insider activity includes HASLER HANS PETER filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.77
P/S
0.00
EV/EBITDA
-0.15
DCF Value
$1.98
FCF Yield
-17392.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
359.8%
ROA
-441.4%
ROIC
-31.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-125.4M | $-2.86 |
| Q4 2025 | $0.00 | $-283.7M | $-25.51 |
| FY 2025 | $0.00 | $-293.4M | $-34.67 |
| Q3 2025 | $0.00 | $-2.7M | $-0.36 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.17
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.